glp-1 pancreatic cancer GLP-1s appear to cut risk. Researchers are asking why and how : NPR Making More Cases of Pancreatic

[12] GoodRx

Preoperative considerations of new long-acting glucagon-like peptide-1receptor agonists in diabetes mellitus

This trend is particularly concerning in developed countries, where sedentary lifestyles and poor dietary habits contribute to the epidemic

No other animals or data points were excluded from any of the in vivo study analyses

According to FDA prescribing information, gallbladder-related adverse events occurred in clinical trials of semaglutide for weight management (Wegovy) at rates of 2.5% versus 1.0% with placebo, and for tirzepatide (Zepbound) at rates of 2.5% versus 1.0% with placebo

Based on the latest results, orforglipron has a better profile than the only approved oral GLP-1 medication